1,682 Shares in Abbott Laboratories (NYSE:ABT) Purchased by Roberts Wealth Advisors LLC

Roberts Wealth Advisors LLC acquired a new position in Abbott Laboratories (NYSE:ABT) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,682 shares of the healthcare product maker’s stock, valued at approximately $223,000.

A number of other hedge funds also recently added to or reduced their stakes in the business. DecisionMap Wealth Management LLC purchased a new stake in shares of Abbott Laboratories during the first quarter valued at about $215,000. ORG Wealth Partners LLC lifted its position in shares of Abbott Laboratories by 7.9% during the first quarter. ORG Wealth Partners LLC now owns 46,155 shares of the healthcare product maker’s stock valued at $6,078,000 after buying an additional 3,371 shares during the last quarter. Global X Japan Co. Ltd. lifted its position in shares of Abbott Laboratories by 8.5% during the first quarter. Global X Japan Co. Ltd. now owns 4,843 shares of the healthcare product maker’s stock valued at $642,000 after buying an additional 379 shares during the last quarter. Premier Path Wealth Partners LLC increased its holdings in shares of Abbott Laboratories by 6.7% during the first quarter. Premier Path Wealth Partners LLC now owns 7,684 shares of the healthcare product maker’s stock valued at $1,019,000 after acquiring an additional 480 shares in the last quarter. Finally, Harrell Investment Partners LLC acquired a new position in shares of Abbott Laboratories during the first quarter valued at about $216,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Sally E. Blount sold 2,600 shares of the stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total transaction of $337,116.00. Following the transaction, the director now owns 34,058 shares in the company, valued at $4,415,960.28. This trade represents a 7.09% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ABT shares. Bank of America upped their price objective on shares of Abbott Laboratories from $133.00 to $150.00 and gave the company a “buy” rating in a report on Monday, March 10th. Citigroup upped their price objective on shares of Abbott Laboratories from $135.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Wells Fargo & Company upped their price objective on shares of Abbott Laboratories from $136.00 to $147.00 and gave the company an “overweight” rating in a report on Thursday, April 17th. Leerink Partnrs upgraded shares of Abbott Laboratories to a “hold” rating in a report on Monday. Finally, Morgan Stanley upped their price objective on shares of Abbott Laboratories from $117.00 to $127.00 and gave the company an “equal weight” rating in a report on Thursday, April 17th. Six analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $142.61.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $132.35 on Friday. The stock has a market capitalization of $230.27 billion, a price-to-earnings ratio of 17.17, a PEG ratio of 2.51 and a beta of 0.73. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23. The firm’s 50 day simple moving average is $132.07 and its 200-day simple moving average is $126.76. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.78 and a quick ratio of 1.27.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.89% and a return on equity of 19.01%. The business had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.38 billion. Analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be given a dividend of $0.59 per share. The ex-dividend date is Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.78%. Abbott Laboratories’s dividend payout ratio (DPR) is 30.61%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.